The estimated Net Worth of Leslie V Norwalk is at least $3.42 Million dollars as of 11 July 2024. Ms. Norwalk owns over 1,000 units of Neurocrine Biosciences stock worth over $1,994,416 and over the last 11 years she sold NBIX stock worth over $620,574. In addition, she makes $804,345 as Independent Director at Neurocrine Biosciences.
Sign up
Ms. Norwalk NBIX stock SEC Form 4 insiders trading
Leslie has made over 6 trades of the Neurocrine Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 1,000 units of NBIX stock worth $70,000 on 11 July 2024.
The largest trade she's ever made was selling 10,590 units of Neurocrine Biosciences stock on 15 March 2024 worth over $550,574. On average, Leslie trades about 477 units every 22 days since 2014. As of 11 July 2024 she still owns at least 16,419 units of Neurocrine Biosciences stock.
You can see the complete history of Ms. Norwalk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Leslie Norwalk biography
Leslie V. Norwalk J.D. serves as Independent Director of the Company. Ms. Norwalk has served on the Board of Directors since September 2019. Since 2007, Ms. Norwalk has served as Strategic Counsel to healthcare companies at Epstein Becker Green, EBG Advisors and National Health Advisors. Ms. Norwalk is an Operating Partner at Enhanced Equity Fund, L.P., a private equity firm, and also serves as an advisor to Warburg Pincus LLC, and Peloton Equity, both private equity firms. She serves as a director of NuVasive, Inc., Endologix, Inc., Providence Service Corporation, Magellan Health, Inc., and Arvinas, Inc., all publicly traded companies, as well as several privately-held healthcare companies. Additionally, she serves as a healthcare, regulatory and policy advisor to several private equity firms. Ms. Norwalk began her career in the public sector as The White House Special Assistant to the Office of Presidential Personnel under the first Bush administration, following which, she practiced law at the Washington, D.C. office of Epstein Becker Green, P.C. From 2001 to 2007 she served in several roles at the Centers for Medicare & Medicaid Services (CMS) under the George W. Bush administration, including serving as Deputy Administrator, and Counselor and Policy Advisor, before assuming the role of Acting Administrator. Ms. Norwalk holds a Juris Doctorate from the George Mason University School of Law and a Bachelor of Arts degree in economics and international relations from Wellesley College.
What is the salary of Leslie Norwalk?
As the Independent Director of Neurocrine Biosciences, the total compensation of Leslie Norwalk at Neurocrine Biosciences is $804,345. There are 9 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
How old is Leslie Norwalk?
Leslie Norwalk is 54, she's been the Independent Director of Neurocrine Biosciences since 2019. There are 15 older and 6 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
What's Leslie Norwalk's mailing address?
Leslie's mailing address filed with the SEC is 2560 GENERAL ARMISTEAD AVE, , AUDUBON, PA, 19403.
Insiders trading at Neurocrine Biosciences
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
What does Neurocrine Biosciences do?
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
What does Neurocrine Biosciences's logo look like?
Complete history of Ms. Norwalk stock trades at Endologix, Magellan Health Inc, Neurocrine Biosciences, Nuvasive Inc, Providence Service Corp, Centene, Globus Medical Inc, and Arvinas Inc
Neurocrine Biosciences executives and stock owners
Neurocrine Biosciences executives and other stock owners filed with the SEC include:
-
Kevin Gorman,
Chief Executive Officer, Director -
Matthew Abernethy,
Chief Financial Officer -
Eric Benevich,
Chief Commercial Officer -
Eiry Roberts,
Chief Medical Officer -
Haig Bozigian,
Chief Development Officer -
Kyle Gano,
Chief Business Development and Strategy Officer -
Dimitri Grigoriadis,
Chief Research Officer -
Dr. Kevin C. Gorman Ph.D.,
CEO & Director -
Dr. Eiry Wyn Roberts,
Chief Medical Officer -
Leslie Norwalk,
Independent Director -
Matthew C. Abernethy,
Chief Financial Officer -
Eric S. Benevich,
Chief Commercial Officer -
Kyle W. Gano,
Chief Bus. Devel. and Strategy Officer -
William Rastetter,
Independent Chairman of the Board -
Stephen Sherwin,
Independent Director -
Richard Pops,
Independent Director -
George Morrow,
Independent Director -
Gary Lyons,
Independent Director -
Todd Tushla,
Investor Relations -
Julie Cooke,
Chief Human Resource Officer -
Shalini Sharp,
Independent Director -
Darin Lippoldt,
Chief Legal Officer and Corporate Secretary -
Malcolm Lloyd-Smith,
Chief Regulatory Officer -
David Boyer,
Chief Corporate Affairs Officer -
Julie S. Cooke,
Chief HR Officer -
Darin M. Lippoldt,
Chief Legal Officer & Corp. Sec. -
Jane Sorensen,
Head of Investor Relations -
Dr. Jude Onyia Ph.D.,
Chief Scientific Officer -
Dr. Dimitri E. Grigoriadis,
Chief Research Officer -
Matt Abernethy,
Chief Financial Officer -
Corinne H Nevinny,
Director -
Christopher Flint O Brien,
Sr. VP & Chief Medical Officer -
Joseph A Mollica,
Director -
David Alexandre C Gros,
President & COO -
Alfred Sandrock,
Director -
Christine A Poon,
Director -
Wylie W Vale,
Director -
Timothy Coughlin,
VP and Chief Financial Officer -
Jensen Margaret E Valeur,
Senior VP and General Counsel -
Partners L P/Ilbiotechnolog...,
-
Johanna Mercier,
Director -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Henry Pan,
Executive VP and CMO -
Wendall Wierenga,
EVP, Research & Development -
Richard J Ranieri,
Sr. VP, Human Resources -
Thomas Mitchell W,
Director -
Ingrid Delaet,
Chief Regulatory Officer -
Paul W Hawran,
Executive VP and CFO -
Paul J Conlon,
Vice President Research (Biol) -
Lawrence Steinman,
Director -
John Saunders,
Vice President Research (Chem) -
Robert J Little,
SVP, Commercial Operations -
D Bruce Campbell,
Senior Vice President -
Jude Onyia,
Chief Scientific Officer